Brokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) Target Price at $103.75

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been assigned an average recommendation of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $102.00.

Several equities analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their price objective on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Piper Sandler assumed coverage on shares of TransMedics Group in a report on Thursday. They set an “overweight” rating and a $95.00 price target on the stock. Morgan Stanley boosted their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. Finally, Oppenheimer boosted their price target on shares of TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a report on Tuesday, February 27th.

TransMedics Group Trading Down 0.2 %

NASDAQ TMDX opened at $73.94 on Friday. TransMedics Group has a twelve month low of $36.42 and a twelve month high of $99.63. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. The stock has a market cap of $2.42 billion, a price-to-earnings ratio of -96.03 and a beta of 2.01. The firm’s 50 day moving average price is $83.45 and its two-hundred day moving average price is $70.01.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The firm had revenue of $81.20 million for the quarter, compared to analysts’ expectations of $68.49 million. During the same period in the previous year, the company posted ($0.21) EPS. The company’s quarterly revenue was up 158.6% compared to the same quarter last year. Equities analysts anticipate that TransMedics Group will post -0.22 EPS for the current year.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 736 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $90.09, for a total value of $66,306.24. Following the completion of the sale, the insider now directly owns 14,375 shares in the company, valued at $1,295,043.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Tamer I. Khayal sold 1,417 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $87.80, for a total value of $124,412.60. Following the completion of the sale, the insider now directly owns 25,185 shares in the company, valued at $2,211,243. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Tamer I. Khayal sold 736 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total transaction of $66,306.24. Following the completion of the sale, the insider now owns 14,375 shares of the company’s stock, valued at $1,295,043.75. The disclosure for this sale can be found here. Over the last three months, insiders sold 92,949 shares of company stock worth $7,710,719. Corporate insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Huntington National Bank acquired a new position in TransMedics Group during the 2nd quarter worth $30,000. Ancora Advisors LLC acquired a new position in TransMedics Group during the 1st quarter worth $38,000. First Horizon Advisors Inc. lifted its position in TransMedics Group by 45.1% during the 1st quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock worth $41,000 after acquiring an additional 169 shares during the last quarter. Belpointe Asset Management LLC lifted its position in TransMedics Group by 51.6% during the 1st quarter. Belpointe Asset Management LLC now owns 558 shares of the company’s stock worth $42,000 after acquiring an additional 190 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in TransMedics Group by 595.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 598 shares of the company’s stock worth $50,000 after acquiring an additional 512 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.